Incretin-based therapies for type 2 diabetes mellitus (Q37483473)

20 August 2017

1 reference

title

Incretin-based therapies for type 2 diabetes mellitus (English)

1 reference

20 August 2017

0 references

2

Daniel J Drucker

1 reference

20 August 2017

Julie A Lovshin

1

1 reference

20 August 2017

1 May 2009

1 reference

Nature Reviews Endocrinology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

262-269

1 reference

20 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.48

20 August 2017

0 references

cites work

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Therapeutic strategies based on glucagon-like peptide 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

The biology of incretin hormones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.48

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

31 March 2020

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Exenatide and rare adverse events

1 reference

12 December 2020

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

12 December 2020

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.48

1 reference

PubMed ID

19444259

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19444259